U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C31H27F2N5O3S2
Molecular Weight 619.7079
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLESATINIB

SMILES

COCCNCc1ccc(-c2cc3c(c(ccn3)Oc4ccc(cc4F)N=C(N=C(Cc5ccc(cc5)F)O)S)s2)nc1

InChI

InChIKey=YRCHYHRCBXNYNU-UHFFFAOYSA-N
InChI=1S/C31H27F2N5O3S2/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42)

HIDE SMILES / InChI

Molecular Formula C31H27F2N5O3S2
Molecular Weight 619.7079
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: http://www.generon.co.uk/amine-oxides-1830/mgcd-265--182002623.html | https://clinicaltrials.gov/ct2/show/NCT02544633

Glesatinib (MGCD265) is an orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. Glesatinib binds to and inhibits the phosphorylation of several receptor tyrosine kinases (RTKs), including the c-Met receptor (hepatocyte growth factor receptor); the Tek/Tie-2 receptor; vascular endothelial growth factor receptor (VEGFR) types 1, 2, and 3; and the macrophage-stimulating 1 receptor (MST1R or RON). Inhibition of these RTKs and their downstream signaling pathways may result in the inhibition of tumor angiogenesis and tumor cell proliferation in tumors overexpressing these RTKs. Studies in a gastric cancer xenograft model revealed that, in addition to the typically reported cellular activities, glesatinib in combination with erlotinib disrupted the glycolysis pathway, suggesting a novel mechanism of action for this drug. Glesatinib has been studied in a variety of advanced solid tumors including NSCLC, as a monotherapy and in combination with either docetaxel or erlotinib. In an ongoing phase 1 study in patients with MET positive or AXL-rearranged advanced solid tumors, glesatinib demonstrated preliminary single-agent activity, with all three patients with MET dysregulated NSCLC (two with METex14 alterations and one with increased GCN) showing significant tumor regression at the first assessment. A phase 2 study is currently recruiting patients with MET-dysregulated (mutated or amplified) advanced or metastatic NSCLC.

Approval Year

PubMed

PubMed

TitleDatePubMed
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
2017 Jan
Patents

Sample Use Guides

MGCD265 (glesatinib) was given orally from 24 mg/m2 daily to 235 mg/m2 twice daily uninterrupted to patients with advanced solid malignancy until disease progression
Route of Administration: Oral
In MKN45 cells the IC50 value of glesatinib was 20 nM
Substance Class Chemical
Created
by admin
on Fri Jun 25 23:17:01 UTC 2021
Edited
by admin
on Fri Jun 25 23:17:01 UTC 2021
Record UNII
7Q29OXD98N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLESATINIB
WHO-DD  
USAN   INN  
Official Name English
MG90265
Code English
MGCD-265
Code English
MGCD265
Code English
MG-90265X
Code English
GLESATINIB [WHO-DD]
Common Name English
GLESATINIB [USAN]
Common Name English
MG-90265
Code English
MG90265X
Code English
BENZENEACETAMIDE, 4-FLUORO-N-(((3-FLUORO-4-((2-(5-(((2-METHOXYETHYL)AMINO)METHYL)-2-PYRIDINYL)THIENO(3,2-B)PYRIDIN-7-YL)OXY)PHENYL)AMINO)THIOXOMETHYL)-
Systematic Name English
GLESATINIB [INN]
Common Name English
N-(3-FLUORO-4-(2-(5-((2-METHOXYETHYLAMINO) METHYL)PYRIDINE-2-YL)THIENO(3,2-B)PYRIDINE-7-YLOXY)PHENYLCARBAMOTHIOYL)-2-(4-FLUOROPHENYL)ACETAMIDE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Fri Jun 25 23:17:01 UTC 2021 , Edited by admin on Fri Jun 25 23:17:01 UTC 2021
NCI_THESAURUS C1967
Created by admin on Fri Jun 25 23:17:01 UTC 2021 , Edited by admin on Fri Jun 25 23:17:01 UTC 2021
Code System Code Type Description
CAS
1044577-56-1
Created by admin on Fri Jun 25 23:17:01 UTC 2021 , Edited by admin on Fri Jun 25 23:17:01 UTC 2021
NO STRUCTURE GIVEN
INN
10217
Created by admin on Fri Jun 25 23:17:01 UTC 2021 , Edited by admin on Fri Jun 25 23:17:01 UTC 2021
PRIMARY
DRUG BANK
DB06302
Created by admin on Fri Jun 25 23:17:01 UTC 2021 , Edited by admin on Fri Jun 25 23:17:01 UTC 2021
PRIMARY
NCI_THESAURUS
C77876
Created by admin on Fri Jun 25 23:17:01 UTC 2021 , Edited by admin on Fri Jun 25 23:17:01 UTC 2021
PRIMARY
FDA UNII
7Q29OXD98N
Created by admin on Fri Jun 25 23:17:01 UTC 2021 , Edited by admin on Fri Jun 25 23:17:01 UTC 2021
PRIMARY
CAS
1072115-99-1
Created by admin on Fri Jun 25 23:17:01 UTC 2021 , Edited by admin on Fri Jun 25 23:17:01 UTC 2021
NO STRUCTURE GIVEN
PUBCHEM
25181472
Created by admin on Fri Jun 25 23:17:01 UTC 2021 , Edited by admin on Fri Jun 25 23:17:01 UTC 2021
PRIMARY
CAS
936694-12-1
Created by admin on Fri Jun 25 23:17:01 UTC 2021 , Edited by admin on Fri Jun 25 23:17:01 UTC 2021
PRIMARY
ChEMBL
CHEMBL254760
Created by admin on Fri Jun 25 23:17:01 UTC 2021 , Edited by admin on Fri Jun 25 23:17:01 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
TARGET -> INHIBITOR
COMPETITIVE INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY